Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR.

A cohort study of patients with moderate-severe psoriasis registered to the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) determined that there was no association between developing a first basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) following treatment with biologic therapy when compared to non-biologic systemic therapies.